UK and Italy CBD regulatory overview and industry landscape (Feb 2019)

UK and Italy CBD regulatory overview and industry landscape (Feb 2019) The passage outlines public regulatory details about CBD and medical cannabis in the UK and Italy, mentions agencies such as the MHRA, FSA, Home Office, and the British Hemp Association, but provides no concrete leads linking high‑profile individuals, financial flows, or misconduct. It is largely descriptive and offers limited investigative value. Key insights: UK legalized prescription medical cannabis in Nov 2018; limited patient access.; Pure CBD not controlled under Misuse of Drugs Act 1971; regulatory loopholes allow widespread retail sales.; FSA announced a consumer‑safety investigation into CBD products in Jan 2019, with possible 18‑month timeline.